Evidence map›Paper›PMID 37333473›Full record

ArticleAvicenna journal of phytomedicine

The effect of crocin and losartan on

Yaser Mohammadi, Mohammad Zangooei, Mahmoud Zardast, Morteza Mamashli, Azam Rezaei Farimani

Open access · greenAbstract read
In one paragraph

Article in Avicenna journal of phytomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Exploring Therapeutic Potential ofCurrent topics in medicinal chemistry · 2026
    Article
  3. Review
  4. Article
  5. Potential therapeutic effects of crocin.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yaser MohammadiQaen School of Nursing and Midwifery, Birjand University of Medical Sciences, Birjand, Iran.
Mohammad ZangooeiDepartment of Clinical Biochemistry, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran.
Mahmoud ZardastMedical Toxicology and Drug Abuse Research Center, Department of Pathology, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran.
Morteza MamashliDepartment of Clinical Biochemistry, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran.
Azam Rezaei FarimaniDepartment of Clinical Biochemistry, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran.
Birjand University of Medical Sciences · IRIranshahr University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Diabetic nephropathy is one of the most common microvascular complications of diabetes mellitus that finally leads to complete loss of kidney function. Therefore, this study aimed to evaluate the effect of crocin and losartan on Materials and Methods: Forty male Wistar rats were randomly divided into five groups (n=8): Untreated control, Diabetic (D), D + crocin, D + losartan, and D + losartan + crocin. Induction of diabetes was performed using streptozotocin (50 mg/kg/ Intraperitoneal injection). At the end of the eight-week period, the rats were sacrificed. Spectrophotometry measured serum glucose, urea, creatinine, and uric acid levels. Microalbumin and creatinine levels were measured in 24-hour urine. Real-time PCR was used to determine the relative expression of the Results: The results showed that hyperglycemia increased biochemical factors associated with diabetes, Conclusion: Our results showed that crocin could improve kidney function in diabetic conditions. In addition, we showed that crocin increases the effectiveness of losartan. Consequently, we suggest that crocin in combination with chemical drugs can be a potential therapeutic agent for diabetes and its complications. Nonetheless, human studies are needed to make firm findings.

Indexed as

CrocinDiabetic nephropathyKidneyLosartanTGF-β

Identifiers

PMID37333473
PMCPMC10274314
OpenAlexW4381158454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.